Open vinoo-igem opened 2 years ago
If we add Cas repressor devices (e.g., https://doi.org/10.1038/ncomms15459, https://www.nature.com/articles/nmeth.2969), when we would definitely want to do this. In this case, the device actually consists of three parts: the Cas, the gRNA expression region, and the targeted promoter.
With Cas used for editing, are there "favorite" sites that people target?
With Cas used for editing, are there "favorite" sites that people target?
I know David Liu's lab typically uses HEK3, DNMT1, RNF2, EMX1, FANCF, RUNX1 and VEGFA to test the efficiency of their prime and base editing variants in human cells.
As we consider what the must-haves and nice-to-haves are for a CRISPR-Cas kit: should we be providing an expression device/plasmid for gRNA paired with a particular Cas? This may all be moot if we want to encourage teams to assemble these as two separate devices instead, and then a MTU.
I imagine there are many considerations here, but to get the ball rolling.